目的 探讨金纳多联合阿托伐他汀钙治疗非急性期脑梗死的临床效果。方法 选取2018-01至2019-01海军青岛特勤疗养中心就诊的120例脑梗死患者,随机分成两组,对照组采用口服金纳多,1~2片/次,2~3次/d。观察组在对照组治疗基础上,加服阿托伐他汀钙片,1次/d,20 mg/次。两组均连续治疗2周,比较两组的治疗效果及NIHSS评分、ApoB/ApoA-l比值、TC/HDL-C比值、MDA、IL-6、IL-1β水平、颈总动脉RI、颈总动脉内径及颈总动脉IMT水平。结果 观察组治疗有效率(91.67%)明显高于对照组(75.00%),差异有统计学意义(χ2=6.000,P<0.05)。两组治疗后NIHSS评分、ApoB/ApoA-l比值、TC/HDL-C比值、MDA、IL-6、IL-1β水平、颈总动脉RI、颈总动脉内径及颈总动脉IMT水平均较治疗前有明显降低,SOD水平显著升高,差异有统计学意义(P<0.05);且观察组改善水平明显优于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率差异无统计学意义。结论 应用金纳多联合他汀类治疗非急性期脑梗死,疗效确切,不良反应较少。
Abstract
Objective To investigate the clinical effect of Ginaton combined with statins against cerebral infarction. Methods One hundred and twenty patients with cerebral infarction treated between January 2018 and January 2019 were randomly divided into two groups. The control group was treated with oral Ginaton, one or two tablets per time and two or three times a day. The patients in the observation group were treated in the same way, but they took atorvastatin calcium tablets 20 mg orally once a day. The treatment lasted two weeks before the clinical effect was compared between the two groups. Results The effective rate of the observation group (91.67%) was significantly higher than that of the control group (75.00%)(χ2=6.000,P<0.05). After treatment, the NIHSS score, apoB/apoa-l ratio, TC/HDL-C ratio, MDA, IL-6, IL-1 β levels, and the RI, inner diameter and IMT level of the common carotid artery in both groups were significantly decreased, while the SOD level was significantly increased (P<0.05). The above indexes were improved more significantly in the observation group than in the control group (P<0.05). The incidence of adverse reactions was not significantly different between the two groups group. Conclusions Ginaton combined with statins is effective in the treatment of cerebral infarction.
关键词
金纳多 /
阿托伐他汀钙片 /
脑梗死 /
疗效
Key words
Ginaton /
atorvastatin calcium tablets /
cerebral infarction /
therapeutic effect
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 郭晓莺, 孙昌友, 高 丽,等. 马来酸桂哌齐特联合丹参川芎嗪注射液治疗脑梗死的疗效[J]. 武警医学, 2020,31(3):211-214.
[2] 张珊珊,陈亚新.阿托伐他汀治疗急性前循环脑梗死临床评价[J].中国药业,2020,29(2):95-97.
[3] Chen J, Li M, Zhu X, et al. Atorvastatin reduces cerebral vasospasm and infarction after aneurysmal subarachnoid hemorrhage in elderly Chinese adults[J]. Aging (Albany NY),2020,12 (3):2939-2951.
[4] 辛 佳,赵喜庆,张 利,等.金纳多注射液联合rt-PA静脉溶栓对急性脑梗死患者神经功能缺损及血清因子的影响[J].医学综述,2019,25(19):3949-3952.
[5] 王芙蓉,宋西刚.金纳多注射液联合奥扎格雷钠治疗急性脑梗死的临床观察及护理[J].中国实用医药,2018,13(35):155-156.
[6] Chalos V, Ende A M, Lingsma H F, et al. National institutes of health stroke scale: an alternative primary outcome measure for trials of acute treatment for ischemic stroke[J]. Stroke,2020,51(1):282-290.
[7] Xie K, Zhao S, Li X. Efficacy and mechanism of butylphthalide combined with atorvastatin calcium tablets in the diagnosis of cerebral infarction using iodol/Fe nanometric contrast agent[J].J Nanosci Nanotechnol,2020,20(12):7356-7361.
[8] 曹志勇,李新玲,沈海林,等.银杏二萜内酯葡胺治疗动脉粥样硬化性脑梗死临床观察[J].中国实用神经疾病杂志, 2018,11(3):279-282.
[9] 逯蕊芳,曹 旸,王玉宁,等.阿托伐他汀联合银杏二萜内酯葡胺注射液治疗急性脑梗死的临床研究[J].现代药物与临床, 2018,33(9):2193-2197.
[10] 孔令宇,马文婷,杨亚勤,等.氯吡格雷联合瑞舒伐他汀对急性脑梗死患者血清炎性因子的影响[J].广东医学,2020,41(2):130-133.
[11] 方钊妍,贝伟剑,罗朵生,等.银杏叶提取物抗氧化机制的网络药理学研究[J].中药新药与临床药理,2020,31(8):942-949.
[12] 程 振.金纳多注射液联合rt-PA静脉溶栓对急性脑梗死患者NIHSS评分及生活质量的影响[J].现代诊断与治疗,2018,29(21):3396-3398.
[13] 刘 玲, 陶瑞明, 杨亚东,等.替罗非班治疗急性脑梗死患者的疗效及对炎性因子的影响[J].心脑血管病防治, 2018, 18(1):39-41.
[14] Ducroux C, Desilles J P, Mawhin M A, et al. Protective effect of apoA1 (apolipoprotein A1)-milano in a rat model of large vessel occlusion stroke[J]. Stroke,2020,51(6):1886-1890.
[15] Zhang H, Zhao X, Wang C, et al. A Preliminary study of the association between apolipoprotein E promoter methylation and atherosclerotic cerebral infarction[J]. J Stroke Cerebrovasc Dis,2019,28 (4):1056-1061.
[16] 吕晓莉.金纳多注射液治疗急性脑梗死的观察及护理体会[J].中国医药指南,2019,17(36):277.
PDF(667 KB)
